What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE diabetes model

Current Medical Research and Opinion

Volumn 20, Issue SUPPL. 1, 2004, Pages

  Palmer, Andrew J ^a   Roze, Stéphane ^a   Valentine, William J ^a   Minshall, Michael E ^b   Lammert, Morten ^a   Oglesby, Alan ^c   Hayes, Clarice ^c   Spinas, Giatgen A ^d  

^a IQVIA   (United States)

^b CORE USA LLC ^*  (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Beta cell function; Costs; Diabetes; Glucagon like peptides; Health economics; Life expectancy; Modelling; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCAGON LIKE PEPTIDE; GLUCOSE; HEMOGLOBIN A1C;

ARTICLE; BLOOD PRESSURE REGULATION; CELL FUNCTION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; INSULIN RESISTANCE; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION;

COMPUTER SIMULATION; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIFE EXPECTANCY; MODELS, ECONOMETRIC; PRESERVATION, BIOLOGICAL; QUALITY-ADJUSTED LIFE YEARS; RISK REDUCTION BEHAVIOR;

EID: 5344260376     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X2024     Document Type: Article

References (22)

1. Powers AC. Diabetes Mellitus. In: Harrison's Principles of Internal Medicine. 15th edn. Editors: Braunwald E, Fauci AS, Kasper DL et al. McGraw-Hill, New York, 2001. Page 2109-16.
2. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317:720-6.
3. UK Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside a randomised controlled trial. UKPDS 41. BMJ 2000; 320:1373-8.
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27(Suppl 1):S15-S35.
5. UK Prospective Diabetes Study Group. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabetic Medicine 1998; 15:297-303.
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study Group. JAMA 1999; 281(21):2005-12.
7. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
8. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4(1):56-9.
9. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51(9):2796-803.
10. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283(4):E745-E752.
11. Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144(12):5149-58.
12. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26(8):2370-7.
13. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51(5):1443-52.
14. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50(7):1562-70.
15. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48(12):2270-6.
16. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta-cell apoptosis. J Biol Chem 2003; 278(1):471-8.
17. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20(Suppl 1):S5-S26.
18. Palmer AJ, Roze S, Valentine W, Minshall ME, Foos V, Lurati F et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20(Suppl. 1).
19. Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med 2002; 19(6):465-9.
20. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 1994; 9(12):702-7.
21. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 1998; 339(6):380-6.
22. Detsky AS, Redelmeier DA. Measuring health outcomes - putting gains into perspective. N Engl J Med 1998; 339(6):402-4.